Andrew L. Pecora, MD, discusses the significance of the long-term findings from the KEYNOTE-942 trial of intismeran autogene ...
ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET ...
Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to ...
Abemaciclib (Verzenio) reduced the risk of progression or death by 62% compared with placebo in patients with advanced ...
The IGNYTE continues to show promising outcomes despite negative FDA decisions.
A novel treatment approach combining triple-oral metronomic chemotherapy with ultra-low-dose immunotherapy (nivolumab; TMC-I ...
SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting ...
The second is the combination of cutaneous toxicity (rash, paronychia) and venous thromboembolism (VTE), which requires ...
Dr. Rodriguez discusses CNS surveillance for Mr. Smith, who has selected subcutaneous (SC) amivantamab plus lazertinib for ...
Dr. Rodriguez walks through the central nervous system (CNS) efficacy data for the three first-line options. She notes that ...
Dr. Rodriguez describes the current period in EGFR-positive lung cancer as one of active change in the first-line landscape: ...
FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results